Showing results (21-30 of 147) with videos related to

Sort By:
Pageof 15
Multiple Sclerosis (Houndmills, Basingstoke, England)|April 8, 2023
Management of vascular risk in people with multiple sclerosis at the time of diagnosis in England: A population-based studyRaffaele Palladino, Ruth Ann Marrie, Azeem Majeed, et al.
Vascular Health and Risk Management|October 24, 2012
The potential benefit of stem cell therapy after stroke: an updateSoma Banerjee, Deborah A Williamson, Nagy Habib, et al.
CNS Drugs|May 12, 2016
Secondary Progressive Multiple Sclerosis: Definition and MeasurementDomenico Plantone, Floriana De Angelis, Anisha Doshi, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|August 5, 2020
Wearable technologies to measure clinical outcomes in multiple sclerosis: A scoping reviewSarah Alexander, Guy Peryer, Emma Gray, et al.
Age and Ageing|November 13, 2010
Human stem cell therapy in ischaemic stroke: a reviewSoma Banerjee, Deborah Williamson, Nagy Habib, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|August 25, 2018
Over three decades study populations in progressive multiple sclerosis have become older and more disabled, but have lower on-trial progression rates: A systematic review and meta-analysis of 43 randomised placebo-controlled trialsRichard S Nicholas, Erika Han, Joel Raffel, et al.
Annals of Clinical and Translational Neurology|July 22, 2024
Investigating cortical hypoxia in multiple sclerosis via time-domain near-infrared spectroscopyThomas Williams, Frédéric Lange, Kenneth J Smith, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|October 18, 2024
Trajectories and management of vascular risk following the diagnosis of multiple sclerosis: A population-based matched cohort study between 1987 and 2018 in EnglandRaffaele Palladino, Jeremy Chataway, Mekha Mathew, et al.
Neurology. Genetics|July 23, 2024
<i>CSF1R</i>-Related Disorder: Prevalence of <i>CSF1R</i> Variants and Their Clinical Significance in the UK PopulationCharles Wade, Kyle Runeckles, Jeremy Chataway, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|August 9, 2023
Assessing heterogeneity of treatment effect in multiple sclerosis trialsMaria Pia Sormani, Jeremy Chataway, David M Kent, et al.
Pageof 15